BioSpace

Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market

Personalized cancer vaccines are getting closer to market. Merck and Moderna just showed successful manufacturing in a large Phase 3 trial, proving they can deliver the goods.

By BioSpace

1 min read
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights